Patent March-In Power: Government Likes Having, Not Using It
This article was originally published in The Pink Sheet Daily
GAO report concludes that although never employed, Bayh-Dole power "is particularly valuable as leverage in informal discussions."
You may also be interested in...
NIH will not invoke its “march-in” authority under the Bayh-Dole Act to allow broader access to Norvir patents, Director Francis Collins says in response to a petition.
Similar to its decision in the Norvir case, NIH says availability, not price, is test of whether the agency can “march-in” on a company’s exclusivity.
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.